Key result
Cre8 amphilimus-eluting DES matches everolimus-eluting DES in diabetes and outperforms it with severe metabolic dysfunction.
Why the study?
PCI is associated with worse clinical and angiographic outcomes among patients with diabetes mellitus compared to non-diabetics, despite second-generation DES improvements.
Does the Cre8 Amphilimus-eluting DES improve clinical and angiographic outcomes in patients with diabetes mellitus undergoing PCI?
Does the Cre8 Amphilimus-eluting DES improve clinical and angiographic outcomes in patients with diabetes mellitus undergoing PCI?
The polymer-free Cre8 Amphilimus-eluting DES demonstrates favorable efficacy and safety profiles in diabetic patients, offering a targeted stent option for this high-risk population.
Despite improved clinical outcomes following the availability of second-generation drug eluting stents (DES), percutaneous coronary intervention (PCI) is associated with worse clinical and angiographic outcomes among patients with diabetes mellitus (DM) than among non-diabetics. The Cre8™ Amphilimus-eluting DES is polymer-free, resulting in a reduced inflammatory response and lower risk of stent thrombosis. It showed equivalent efficacy and safety in diabetic and non-diabetic populations, a unique finding among DES studies. These findings were confirmed in a real-world study called INVESTIG8. Another real-world study, pARTicip8, is ongoing. The RESERVOIR clinical trial recruited patients with diabetes mellitus and showed noninferiority of the Cre8 DES compared to an everolimus-eluting DES but showed a statistical superiority of Cre8 in diabetic patients with higher metabolic dysfunctions. The Cre8 DES is therefore a valuable option for this important patient population.
No takes yet. Share an insight, caveat, or question.
Didier Carrié (2016) conducted a review in Diabetes Mellitus. Cre8 Amphilimus-eluting DES vs. Everolimus-eluting DES was evaluated. The Cre8 Amphilimus-eluting DES was noninferior to everolimus-eluting DES in patients with diabetes mellitus, and showed statistical superiority in those with higher metabolic dysfunctions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: